Yael Mauer, MD, MPH, discusses the patient population who benefits most from interventions with glucagon-like peptide-1 (GLP-1) therapies and explores the underlying mechanisms at work.
At an Institute for Value-Based Medicine® event hosted in conjunction with Cleveland Clinic, Yael Mauer, MD, MPH, Department of Endocrinology, Diabetes, and Metabolism, presented on the current state of knowledge in glucagon-like peptide-1 (GLP-1) receptor agonists. To elaborate on this topic in more detail, Mauer joined The American Journal of Managed Care® for an interview to discuss the patients who can derive the most benefits from these therapies and how these medications affect the body to influence improved patient outcomes.
Transcript
What specific patient profiles or characteristics might benefit most from the GLP-1 class of medications, and how can health care providers effectively identify and tailor treatment approaches?
So, thank you for that question. That is a really good question. I think obesity is multifactorial, and we also have a lot of different tools to address obesity, so choosing the right approach is key in being able to help our patients. I think patients who would particularly benefit from GLP-1 receptor agonists are those who have difficulty with appetite control and cravings. But [they] are also ideal for patients who have metabolic disease like high blood pressure, or high cholesterol, or high blood sugars, because this medication provides a lot of metabolic benefits by lowering blood pressure, by lowering blood sugar, by lowering cholesterol. These medications decrease the chances that patients will develop diabetes if they already have elevated blood sugars. It also could be ideal for patients who have a family history of cardiovascular disease, because those patients are also at an elevated cardiovascular risk.
Can you elaborate on any recent insights or emerging research that further elucidate the underlying pathways through which these medications exert their anti-obesity effects?
I think we know some of the pathways by which the medications work, but some of the pathways we're still discovering about how the medications work. I would say mostly the medications serve their anti-obesity effects by stimulating areas of the brain that promote satiety and inhibiting areas of the brain that promote hunger, making patients feel fuller and less hungry. They also slightly increase thier energy expenditure by stimulating thermogenesis in brown adipose tissue. And one last pathway is that they slow gastric emptying, so the food sits in the in the stomach for longer periods of time, promoting satiety and promoting satiety for longer periods.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Shelly Lanning on How Employers Can Reduce Costs by Bridging Gaps in Women's Health Care
May 3rd 2024In a presentation at the Greater Philadelphia Business Coalition on Health Women’s Health Summit, Shelly Lanning, cofounder and president of Visana Health, addressed the need for comprehensive approaches in women’s health care and their coverage options.
Read More